-
Company Insights
New![]()
Innovation and Patenting activity of Hanmi Semiconductor Co., Ltd. Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hanmi Semiconductor Co., Ltd. Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
New![]()
Innovation and Patenting activity of Hanmi Pharmaceuticals Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hanmi Pharmaceuticals Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HCP-2202 in Gastric Ulcers
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2202 in Gastric Ulcers Drug Details: HCP-2202 is under development for the treatment of unspecified cardiovascular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HCP-2202 in Duodenal Ulcer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2202 in Duodenal Ulcer Drug Details: HCP-2202 is under development for the treatment of unspecified cardiovascular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HCP-2102 in Idiopathic (Essential) Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2102 in Idiopathic (Essential) HypertensionDrug Details:HCP-2102 is under development for the treatment of essential hypertension.Report CoverageThe...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HIP-0612 in Gastric Ulcers
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HIP-0612 in Gastric Ulcers Drug Details: HIP-0612 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HCP-1803 in Idiopathic (Essential) Hypertension
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HCP-1803 in Idiopathic (Essential) Hypertension Drug Details: HCP-1803 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Belvarafenib in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Belvarafenib in Pancreatic Cancer Drug Details: Belvarafenib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HM-21001 in Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HM-21001 in Glioblastoma Multiforme (GBM) Drug Details:HM-21001 is under development for the treatment of glioblastoma multiforme....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Macimorelin Acetate in Growth Hormone Deficiency
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macimorelin Acetate in Growth Hormone Deficiency Drug Details: Macimorelin acetate (AEZS-130) is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.